Company Overview of DermTech, Inc.
DermTech International, a molecular diagnostic company, is engaged in developing and marketing gene expression tests to facilitate the diagnosis of dermatologic conditions. The company offers Adhesive Skin Sample Collection Kit, which consists of adhesive patches, instructions for use, a marking pen for lesion outlining, and a pre-addressed and prepaid return shipping pack. Its Adhesive Skin Sample Collection Kit allows for the collection of skin samples with minimal patient discomfort. The company also provides Pigmented Lesion Assay for reducing unnecessary surgical biopsy procedures and enhancing diagnostic accuracy; ribonucleic acid extraction services; and a smart phone based photoinfor...
11099 North Torrey Pines Road
La Jolla, CA 92037
Founded in 1995
Key Executives for DermTech, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Principal Financial & Accounting Officer, Secretary and Treasurer
Director of Business Administration
Compensation as of Fiscal Year 2016.
DermTech, Inc. Key Developments
DermTech, Inc. Announces Validation Study Publication
Oct 5 16
DermTech, Inc. announced the publication of the "Development and Validation of a Non-Invasive 2-Gene Molecular Assay for Cutaneous Melanoma", in theJournal of the American Academy of Dermatology(Ms.No. JAAD-D-16-00647R1). This validation study sought to provide clinicians with a differentiated and accurate noninvasive diagnostic modality. A 2-gene classification method based on LINC00518 and preferentially expressed antigen in melanoma gene expression (PRAME) was evaluated and validated in 555 pigmented lesions (157 training and 398 validation samples) obtained noninvasively via adhesive patch biopsy. Results were compared with standard histopathologic assessment in lesions with a consensus diagnosis among 3 experienced dermatopathologists. In 398 validation samples, LINC00518 and/or PRAME detection appropriately differentiated melanoma from non-melanoma samples with a sensitivity of 91% and a specificity of 69%. LINC00518 and PRAME were established in both melanoma samples obtained via non-invasive adhesive patch biopsy and underlying FFPE samples of surgically excised primary melanomas and in melanoma lymph node metastases. This newly published validation study demonstrates how non-invasive pigmented lesion assay classifies clinically difficult to differentiate pigmented lesions into melanoma and non-melanoma groups. It offers dermatologists a tool to help with diagnostic challenges that may be inherently linked to the visual image and pattern recognition approach.
DermTech, Inc. Names Mr. Matthew Posard to the Board of Directors
Jul 11 16
DermTech, Inc. announced it has added Mr. Matthew Posard to its board of directors. Additionally, the company announced the continued expansion of its commercial team with regional sales personnel. Mr. Posard held influential leadership roles with companies including Illumina, Trovagene, Biosite/Alere and Gen-Probe.
DermTech, Inc. Announces Sales and Marketing Collaboration with Dermpath Diagnostics
Mar 2 16
DermTech, Inc. announced a sales and marketing collaboration with Dermpath Diagnostics. Dermpath Diagnostics is a business of Quest Diagnostics Incorporated. Under the arrangement, Dermpath Diagnostics will provide specialty dermatology representatives in up to 10 regional territories across the United States to assist DermTech in marketing its Pigmented Lesion Assay (PLA) for assessing melanocytic lesions (nevi and melanoma) via gene expression.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 7, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries